A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Amivantamab (Primary) ; Lazertinib (Primary) ; Osimertinib
- Indications Brain metastases; Liver metastases; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MARIPOSA
- Sponsors Janssen Research & Development; Janssen-Cilag
- 30 Aug 2024 According to Onco360 media release, company has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE (lazertinib) approved for the first-line treatment, in combination with RYBREVANT (amivantamab-vmjw) as a chemotherapy-free regimen, of adult patients with metastatic non-small cell lung cancer (NSCLC)
- 27 Aug 2024 According to Johnson & Johnson media release, data from this trial to be featured at the 2024 World Conference on Lung Cancer (WCLC), (Sept 7-10) in San Diego, CA and the European Society for Medical Oncology (ESMO) 2024 Congress, (Sept 13-17) in Barcelona, Spain.
- 20 Aug 2024 According to a Johnson & Johnson media release, results from this study were published in The New England Journal of Medicine and in Annals of Oncology.